Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 14:06, 24 July 2010 editWereSpielChequers (talk | contribs)Bureaucrats, Administrators343,926 editsm Adding category Category:Drugs; removed {{uncategorized}} (using HotCat)← Previous edit		Latest revision as of 09:49, 10 January 2024 edit undoMaxim Masiutin (talk | contribs)Extended confirmed users, IP block exemptions, Pending changes reviewers31,058 edits Added s2cid. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.
(33 intermediate revisions by 24 users not shown)
Line 1:		Line 1:
			{{Short description|Chemical compound}}
	{{drugbox
			{{cs1 config|name-list-style=vanc}}
⚫	| IUPAC_name = (S)-(4-fluorophenyl)-(3--oxadiazol-5-yl]piperidin-1-yl)methanone
			{{Drugbox
	| image = ADX-47273_structure.png
			| Watchedfields = changed
⚫	| width = 200
			| verifiedrevid = 477346495
⚫	| CAS_number =
		⚫	| IUPAC_name = (S)-(4-fluorophenyl)-(3--oxadiazol-5-yl]piperidin-1-yl)methanone
⚫	| ATC_prefix =
			| image = ADX-47273.svg
⚫	| ATC_suffix =
		⚫	| width = 200
⚫	| PubChem = 11383075
⚫	| IUPHAR_ligand = 1420
⚫	| DrugBank =
⚫	| C=20|H=17|F=2|N=3|O=2
	| molecular_weight = 369.364 g/mol
	| smiles = c4cc(F)ccc4-c3nc(on3)C(C2)CCCN2C(=O)c1ccc(F)cc1
⚫	| bioavailability =
⚫	| protein_bound =
⚫	| metabolism =
⚫	| elimination_half-life =
⚫	| excretion =
⚫	| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	| pregnancy_US = <!-- A / B / C / D / X -->
⚫	| pregnancy_category=
⚫	| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫	| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫	| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫	| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫	| legal_status =
⚫	| routes_of_administration =
⚫	}}
			<!--Clinical data-->
⚫	'''ADX-47273''' is a drug used in scientific research which acts as a ] selective for the ] subtype ].<ref name="pmid16722652">{{cite journal |author=de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ |title=Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes |journal=Journal of Medicinal Chemistry |volume=49 |issue=11 |pages=3332–44 |year=2006 |month=June |pmid=16722652 |doi=10.1021/jm051252j |url=}}</ref> It has ] and ] effects in animal studies,<ref name="pmid18753411">{{cite journal |author=Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL |title=ADX47273 -oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=327 |issue=3 |pages=827–39 |year=2008 |month=December |pmid=18753411 |doi=10.1124/jpet.108.136580 |url=}}</ref> and has been used as a ] to develop improved derivatives.<ref name="pmid19197923">{{cite journal |author=Engers DW, Rodriguez AL, Williams R, Hammond AS, Venable D, Oluwatola O, Sulikowski GA, Conn PJ, Lindsley CW |title=Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 |journal=Chemmedchem |volume=4 |issue=4 |pages=505–11 |year=2009 |month=April |pmid=19197923 |doi=10.1002/cmdc.200800357 |url= |pmc=2865690}}</ref>
			| tradename =
		⚫	| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
		⚫	| pregnancy_US = <!-- A / B / C / D / X -->
		⚫	| pregnancy_category =
		⚫	| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
		⚫	| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
		⚫	| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
		⚫	| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
		⚫	| legal_status =
		⚫	| routes_of_administration =
			<!--Pharmacokinetic data-->
		⚫	| bioavailability =
		⚫	| protein_bound =
		⚫	| metabolism =
		⚫	| elimination_half-life =
		⚫	| excretion =
			<!--Identifiers-->
			| CAS_number_Ref = {{cascite|correct|??}}
		⚫	| CAS_number = 851881-60-2
			| CAS_supplemental = <BR>851881-59-9 (''R'' isomer),<BR>837413-22-6 (racemate)
			| UNII_Ref = {{fdacite|correct|FDA}}
			| UNII = 4C4P7L0W63
		⚫	| ATC_prefix =
		⚫	| ATC_suffix =
			| ChEMBL_Ref = {{ebicite|correct|EBI}}
			| ChEMBL = 381055
		⚫	| PubChem = 11383075
		⚫	| IUPHAR_ligand = 1420
			| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
		⚫	| DrugBank =
			| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
			| ChemSpiderID = 9557988
			<!--Chemical data-->
		⚫	| C=20 | H=17 | F=2 | N=3 | O=2
			| smiles = FC1=CC=C(C(N2CCC(C2)C3=NC(C4=CC=C(F)C=C4)=NO3)=O)C=C1
			| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
			| StdInChI = 1S/C20H17F2N3O2/c21-16-7-3-13(4-8-16)18-23-19(27-24-18)15-2-1-11-25(12-15)20(26)14-5-9-17(22)10-6-14/h3-10,15H,1-2,11-12H2/t15-/m0/s1
			| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
			| StdInChIKey = VXQCCZHCFBHTTD-HNNXBMFYSA-N
		⚫	}}
		⚫	'''ADX-47273''' is a research pharmaceutical developed by ] which acts as a ] (PAM) selective for the ] subtype ].<ref name="pmid16722652">{{cite journal |vauthors =de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ |title=Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes |journal=Journal of Medicinal Chemistry |volume=49 |issue=11 |pages=3332–44 |date=June 2006 |pmid=16722652 |doi=10.1021/jm051252j }}</ref><ref>{{cite journal|last1=Stauffer|first1=Shaun R.|title=Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu5)|journal=ACS Chemical Neuroscience|date=17 August 2011|volume=2|issue=8|pages=450–470|doi=10.1021/cn2000519|pmc=3369763|pmid=22860171}}</ref> It has ] and ] effects in animal studies,<ref name="pmid18753411">{{cite journal |vauthors =Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL |title=ADX47273 -oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=327 |issue=3 |pages=827–39 |date=December 2008|pmid=18753411 |doi=10.1124/jpet.108.136580 |s2cid=19362501 }}</ref> and has been used as a ] to develop improved derivatives.<ref name="pmid19197923">{{cite journal |vauthors =Engers DW, Rodriguez AL, Williams R, Hammond AS, Venable D, Oluwatola O, Sulikowski GA, Conn PJ, Lindsley CW |title=Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 |journal=ChemMedChem |volume=4 |issue=4 |pages=505–11 |date=April 2009 |pmid=19197923 |doi=10.1002/cmdc.200800357 |pmc=2865690}}</ref>
	{{pharm-stub}}
			==See also==
			* ]
			* ]
	== References ==		==References==
	{{reflist}}		{{Reflist|2}}
			{{Metabotropic glutamate receptor modulators}}
	{{Glutamate_receptor_ligands}}
		⚫	]
			]
			{{nervous-system-drug-stub}}
⚫	]